|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Here, through integrating clinical data and a series of functional experiments, we found that lncRNA JPX expression is significantly upregulated in NSCLC tissues compared with that in paired adjacent normal tissues from two independent datasets and significantly associated with a poor survival and other malignant phenotypes (tumor stage, tumor volume) of NSCLC.
|
31253987 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The potential suppressive role of XIST and JPX on HCC was verified by cell functional assays and tumor formation assay using a xenograft model.
|
30091314 |
2018 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
JPX could predict the poor prognosis in patients with ovarian cancer, which could promote the tumor cell proliferation, invasion and migration in human ovarian cancer cell lines and inhibited the cell apoptosis through activating PI3K/Akt/mTOR signaling pathway.
|
30556851 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
JPX and XIST expression was significantly decreased in HCC pathologic specimens, compared to adjacent tissue, which correlated with HCC progression and increased miR-155-5p expression.
|
30091314 |
2018 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Downregulated JPX and XIST may serve as novel biomarkers of poor prognosis in HCC.
|
27776968 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These findings reveal the mechanism of X-chromosome lncRNA JPX and its core regulatory circuitry JPX/miR-145-5p/CCND2 in the development and progression of NSCLC, which bring us closer to an understanding of the molecular drivers of NSCLC cancer.
|
31253987 |
2019 |
|
Malignant Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
JPX increases expression levels of XIST in HCC cells, which suppresses HCC development by sponging the cancer promoting miR-155-5p.
|
30091314 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX could predict the poor prognosis in patients with ovarian cancer, which could promote the tumor cell proliferation, invasion and migration in human ovarian cancer cell lines and inhibited the cell apoptosis through activating PI3K/Akt/mTOR signaling pathway.
|
30556851 |
2018 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX could predict the poor prognosis in patients with ovarian cancer, which could promote the tumor cell proliferation, invasion and migration in human ovarian cancer cell lines and inhibited the cell apoptosis through activating PI3K/Akt/mTOR signaling pathway.
|
30556851 |
2018 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
MTT assay, colony formation and scratch assay showed the repression of JPX and resulted with significantly decreased in cell proliferation, invasion and migration of OVCAR-3 cells compared with the control (p < 0.05).
|
30556851 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
AlteredExpression
|
group |
BEFREE |
JPX increases expression levels of XIST in HCC cells, which suppresses HCC development by sponging the cancer promoting miR-155-5p.
|
30091314 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX could predict the poor prognosis in patients with ovarian cancer, which could promote the tumor cell proliferation, invasion and migration in human ovarian cancer cell lines and inhibited the cell apoptosis through activating PI3K/Akt/mTOR signaling pathway.
|
30556851 |
2018 |
|
Uveal melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Intriguingly, XIST lncRNA serves as a potential target of CANT1, and JPX or FTX lncRNA subsequently serves as a contextual hinge to activate a novel CANT1-JPX/FTX-XIST long non-coding (lncing) pathway in UM.
|
28330694 |
2017 |
|
Embryonal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have also identified additional sense transcripts in EC and female somatic cells and demonstrate that the 5' flanking JPX/ENOX gene is expressed from both the active and the inactive X chromosome in somatic cell hybrids, delimiting the extent of inactive X-specific transcriptional control in somatic cells.
|
12906856 |
2003 |
|
Lymphoid leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX-9 is a subclone of a non-ATL human lymphocytic leukemia cell line, Jurkat, and was established by introducing a metallothionein promoter-driven Tax expression plasmid.
|
9070245 |
1997 |
|
Leukemia, T-Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX-9 is a subclone of a non-ATL human lymphocytic leukemia cell line, Jurkat, and was established by introducing a metallothionein promoter-driven Tax expression plasmid.
|
9070245 |
1997 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
JPX-9 is a subclone of a non-ATL human lymphocytic leukemia cell line, Jurkat, and was established by introducing a metallothionein promoter-driven Tax expression plasmid.
|
9070245 |
1997 |